GlobeNewsWire
08 Apr 2026, 13:07 UTC · 24w ago
Verdict
Headline takes no side. We score MSB +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Mesoblast has received FDA clearance of its IND to proceed directly to a registrational trial for Ryoncil in children with Duchenne muscular dystrophy (DMD).
More positive than 99% of claims this week
The company is implementing a commercial strategy to double net revenues as Ryoncil approaches a US$100M net revenue milestone.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
Mesoblast has acquired a patented CAR technology platform from the Mayo Clinic to enhance its proprietary MSC products.
More positive than 85% of claims this week
The Phase 3 trial for chronic low back pain (CLBP) is scheduled to close enrollment by the end of April 2026.
More positive than 77% of claims this week
The adult SR-aGvHD trial has been cleared by the central institutional review board, with the first sites activating this quarter.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced significant commercial progress, a strategy to double net revenues, FDA clearances for new trials, and the acquisition of a new technology platform.
More positive than 98% of ticker scores this week
The company announced significant commercial progress, a strategy to double net revenues, FDA clearances for new trials, and the acquisition of a new technology platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
32m ago
−36.3%
Price is moving against the score
$20.17 vs $31.68 close before publication (Apr 7) · not market-adjusted
MSB chart →
